Xbrane Biopharma

Board/Management Information • Sep 28, 2020

New Interim CFO in Xbrane Biopharma AB (publ)

Xbrane Biopharma AB (publ) ("Xbrane" or "the company") announces today that Margareta Hagman will take on the position as interim CFO from September 30, 2020 until a new CFO is in place. Margareta will be part of the management team during the time as interim CFO. Margareta has an extensive experience as CFO from BioGaia AB and holds board positions in two listed companies.

As previously announced, Susanna Helgesen will leave her position as CFO as of September 30, 2020. The recruitment of a new permanent CFO is ongoing.

"I want to thank Susanna for her strong efforts as CFO for Xbrane. She has been critical in our growth journey so far and especially in the process of getting on Nasdaq's main list. I want to wish her all the best in her future career", says Martin Åmark, CEO.

Contacts

Martin Åmark, CEO/ IR M: +46 (0) 763-093 777 E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Attachments

New Interim CFO in Xbrane Biopharma AB (publ)